2. Academic Validation
  3. Reduction of Progranulin-Induced Breast Cancer Stem Cell Propagation by Sortilin-Targeting Cyclotriazadisulfonamide (CADA) Compounds

Reduction of Progranulin-Induced Breast Cancer Stem Cell Propagation by Sortilin-Targeting Cyclotriazadisulfonamide (CADA) Compounds

  • J Med Chem. 2021 Sep 9;64(17):12865-12876. doi: 10.1021/acs.jmedchem.1c00943.
Karoline Berger 1,  Eva Pauwels 2,  Gabrielle Parkinson 1,  Göran Landberg 1,  Truc Le 3,  Violeta G Demillo 3,  Liezel A Lumangtad 3 4,  Dylan E Jones 3,  Md Azizul Islam 3,  Ryan Olsen 3,  Topprasad Kapri 3,  Amarawan Intasiri 3,  Kurt Vermeire 2,  Sara Rhost 1,  Thomas W Bell 3
Affiliations

Affiliations

  • 1 Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 413 90 Gothenburg, Sweden.
  • 2 KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, 3000 Leuven, Belgium.
  • 3 Department of Chemistry, University of Nevada, Reno, Nevada 89557-0216, United States.
  • 4 Nanosyn, 3100 Central Expressway, Santa Clara, California 95051, United States.
PMID: 34428050 DOI: 10.1021/acs.jmedchem.1c00943
Abstract

Cyclotriazadisulfonamide (CADA) compounds selectively down-modulate two human proteins of potential therapeutic interest, cluster of differentiation 4 (CD4) and sortilin. Progranulin is secreted from some breast Cancer cells, causing dedifferentiation of receiving Cancer cells and Cancer stem cell proliferation. Inhibition of progranulin binding to sortilin, its main receptor, can block progranulin-induced metastatic breast Cancer using a triple-negative in vivo xenograft model. In the current study, seven CADA compounds (CADA, VGD020, VGD071, TL020, TL023, LAL014, and DJ010) were examined for reduction of cellular sortilin expression and progranulin-induced breast Cancer stem cell propagation. In addition, inhibition of progranulin-induced mammosphere formation was examined and found to be most significant for TL020, TL023, VGD071, and LAL014. Full experimental details are given for the synthesis and characterization of the four new compounds (TL020, TL023, VGD071, and DJ010). Comparison of solubilities, potencies, and cytotoxicities identified VGD071 as a promising candidate for future studies using mouse breast Cancer models.

Figures
Products